|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HCAR2 |
Gene summary for HCAR2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HCAR2 | Gene ID | 338442 |
| Gene name | hydroxycarboxylic acid receptor 2 | |
| Gene Alias | GPR109A | |
| Cytomap | 12q24.31 | |
| Gene Type | protein-coding | GO ID | GO:0001776 | UniProtAcc | Q8TDS4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 338442 | HCAR2 | LZE8T | Human | Esophagus | ESCC | 3.25e-09 | 4.57e-01 | 0.067 |
| 338442 | HCAR2 | LZE20T | Human | Esophagus | ESCC | 9.52e-06 | 3.73e-01 | 0.0662 |
| 338442 | HCAR2 | LZE21T | Human | Esophagus | ESCC | 1.88e-09 | 9.59e-01 | 0.0655 |
| 338442 | HCAR2 | P1T-E | Human | Esophagus | ESCC | 6.33e-07 | 9.94e-01 | 0.0875 |
| 338442 | HCAR2 | P2T-E | Human | Esophagus | ESCC | 5.50e-15 | 7.39e-01 | 0.1177 |
| 338442 | HCAR2 | P4T-E | Human | Esophagus | ESCC | 1.43e-19 | 9.44e-01 | 0.1323 |
| 338442 | HCAR2 | P5T-E | Human | Esophagus | ESCC | 2.93e-19 | 7.02e-01 | 0.1327 |
| 338442 | HCAR2 | P8T-E | Human | Esophagus | ESCC | 5.97e-49 | 1.56e+00 | 0.0889 |
| 338442 | HCAR2 | P9T-E | Human | Esophagus | ESCC | 3.79e-03 | 2.91e-01 | 0.1131 |
| 338442 | HCAR2 | P10T-E | Human | Esophagus | ESCC | 7.09e-04 | 1.17e-01 | 0.116 |
| 338442 | HCAR2 | P11T-E | Human | Esophagus | ESCC | 2.05e-13 | 1.87e+00 | 0.1426 |
| 338442 | HCAR2 | P12T-E | Human | Esophagus | ESCC | 3.86e-38 | 9.59e-01 | 0.1122 |
| 338442 | HCAR2 | P15T-E | Human | Esophagus | ESCC | 3.19e-05 | 3.24e-01 | 0.1149 |
| 338442 | HCAR2 | P20T-E | Human | Esophagus | ESCC | 3.99e-26 | 1.51e+00 | 0.1124 |
| 338442 | HCAR2 | P21T-E | Human | Esophagus | ESCC | 1.63e-52 | 1.86e+00 | 0.1617 |
| 338442 | HCAR2 | P22T-E | Human | Esophagus | ESCC | 1.22e-15 | 7.34e-01 | 0.1236 |
| 338442 | HCAR2 | P23T-E | Human | Esophagus | ESCC | 1.54e-23 | 1.91e+00 | 0.108 |
| 338442 | HCAR2 | P24T-E | Human | Esophagus | ESCC | 5.64e-06 | 7.48e-01 | 0.1287 |
| 338442 | HCAR2 | P26T-E | Human | Esophagus | ESCC | 3.71e-76 | 1.91e+00 | 0.1276 |
| 338442 | HCAR2 | P27T-E | Human | Esophagus | ESCC | 2.74e-30 | 9.85e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1904951111 | Esophagus | ESCC | positive regulation of establishment of protein localization | 216/8552 | 319/18723 | 1.01e-15 | 6.86e-14 | 216 |
| GO:0051222111 | Esophagus | ESCC | positive regulation of protein transport | 204/8552 | 303/18723 | 1.56e-14 | 8.38e-13 | 204 |
| GO:0009895111 | Esophagus | ESCC | negative regulation of catabolic process | 201/8552 | 320/18723 | 3.88e-10 | 1.05e-08 | 201 |
| GO:0002262111 | Esophagus | ESCC | myeloid cell homeostasis | 104/8552 | 157/18723 | 1.49e-07 | 2.36e-06 | 104 |
| GO:0048872111 | Esophagus | ESCC | homeostasis of number of cells | 163/8552 | 272/18723 | 1.40e-06 | 1.69e-05 | 163 |
| GO:00718871 | Esophagus | ESCC | leukocyte apoptotic process | 65/8552 | 106/18723 | 8.39e-04 | 4.32e-03 | 65 |
| GO:000930617 | Esophagus | ESCC | protein secretion | 190/8552 | 359/18723 | 3.22e-03 | 1.34e-02 | 190 |
| GO:003559217 | Esophagus | ESCC | establishment of protein localization to extracellular region | 190/8552 | 360/18723 | 3.77e-03 | 1.53e-02 | 190 |
| GO:007169210 | Esophagus | ESCC | protein localization to extracellular region | 193/8552 | 368/18723 | 5.01e-03 | 1.92e-02 | 193 |
| GO:00160427 | Esophagus | ESCC | lipid catabolic process | 168/8552 | 320/18723 | 7.97e-03 | 2.84e-02 | 168 |
| GO:005070810 | Esophagus | ESCC | regulation of protein secretion | 142/8552 | 268/18723 | 9.31e-03 | 3.24e-02 | 142 |
| GO:00192168 | Esophagus | ESCC | regulation of lipid metabolic process | 172/8552 | 331/18723 | 1.20e-02 | 4.02e-02 | 172 |
| GO:005071416 | Esophagus | ESCC | positive regulation of protein secretion | 76/8552 | 137/18723 | 1.32e-02 | 4.31e-02 | 76 |
| GO:190495119 | Oral cavity | OSCC | positive regulation of establishment of protein localization | 196/7305 | 319/18723 | 2.89e-16 | 2.20e-14 | 196 |
| GO:005122219 | Oral cavity | OSCC | positive regulation of protein transport | 187/7305 | 303/18723 | 7.37e-16 | 5.49e-14 | 187 |
| GO:000989519 | Oral cavity | OSCC | negative regulation of catabolic process | 180/7305 | 320/18723 | 2.44e-10 | 6.86e-09 | 180 |
| GO:000226220 | Oral cavity | OSCC | myeloid cell homeostasis | 98/7305 | 157/18723 | 2.29e-09 | 5.34e-08 | 98 |
| GO:004887220 | Oral cavity | OSCC | homeostasis of number of cells | 152/7305 | 272/18723 | 1.08e-08 | 2.23e-07 | 152 |
| GO:0071887 | Oral cavity | OSCC | leukocyte apoptotic process | 60/7305 | 106/18723 | 1.78e-04 | 1.21e-03 | 60 |
| GO:000930610 | Oral cavity | OSCC | protein secretion | 169/7305 | 359/18723 | 1.04e-03 | 5.34e-03 | 169 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HCAR2 | SNV | Missense_Mutation | c.121N>C | p.Gly41Arg | p.G41R | Q8TDS4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0WW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| HCAR2 | SNV | Missense_Mutation | rs201097098 | c.757N>T | p.Arg253Cys | p.R253C | Q8TDS4 | protein_coding | tolerated(0.17) | possibly_damaging(0.806) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HCAR2 | insertion | Nonsense_Mutation | novel | c.544_545insAACTACTCCACACTGCAAAGTAAGAAAGAGACACAGACACTGAGC | p.Ile182delinsLysLeuLeuHisThrAlaLysTerGluArgAspThrAspThrGluLeu | p.I182delinsKLLHTAK*ERDTDTEL | Q8TDS4 | protein_coding | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| HCAR2 | insertion | Frame_Shift_Ins | novel | c.65_66insGAGAAACAGTTGGGCTGTTGCATCGAGT | p.Asp23ArgfsTer11 | p.D23Rfs*11 | Q8TDS4 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
| HCAR2 | SNV | Missense_Mutation | rs769715682 | c.665N>A | p.Arg222Gln | p.R222Q | Q8TDS4 | protein_coding | tolerated(0.2) | benign(0.312) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| HCAR2 | SNV | Missense_Mutation | c.812C>G | p.Ser271Trp | p.S271W | Q8TDS4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HCAR2 | SNV | Missense_Mutation | c.185N>A | p.Ser62Asn | p.S62N | Q8TDS4 | protein_coding | tolerated(0.23) | benign(0.23) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HCAR2 | SNV | Missense_Mutation | c.733N>T | p.Leu245Phe | p.L245F | Q8TDS4 | protein_coding | tolerated(0.22) | possibly_damaging(0.588) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HCAR2 | SNV | Missense_Mutation | c.139N>T | p.Leu47Phe | p.L47F | Q8TDS4 | protein_coding | tolerated(0.11) | possibly_damaging(0.612) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| HCAR2 | SNV | Missense_Mutation | c.781N>G | p.Ser261Ala | p.S261A | Q8TDS4 | protein_coding | tolerated(0.88) | benign(0.001) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 338442 | HCAR2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | NIACIN RECEPTOR AGONIST | |||
| 338442 | HCAR2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | NIACIN | NIACIN | 25737085 | |
| 338442 | HCAR2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | MK-0354 | CHEMBL456145 | ||
| 338442 | HCAR2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | agonist | 178102416 | ||
| 338442 | HCAR2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | allosteric modulator | 178102419 | ||
| 338442 | HCAR2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | agonist | 178102413 | ||
| 338442 | HCAR2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | agonist | 135649840 | ||
| 338442 | HCAR2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | agonist | 178102418 | ||
| 338442 | HCAR2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | MK-1903 | |||
| 338442 | HCAR2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | agonist | 178102409 |
| Page: 1 2 3 4 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |